Resectable Pancreatic Adenocarcinomas following Neoadjuvant Chemotherapy with Gemcitabine Plus S-1: Two Case Reports of Opposite Oncological Outcomes
Neoadjuvant GS therapy is potentially expected to have a significant therapeutic effect as the pCR. Nevertheless, even after surgical resection, some patients still exhibit extremely poor prognosis. Therefore, it is necessary to clarify their clinical characteristics.
Authors
- Noriyoshi Fukushima (ORCID: https://orcid.org/0000-0002-4522-9007)
- Hirotoshi Kawata
- Yoshiyuki Meguro
- Hideyo Miyato
- Kazue Morishima (ORCID: https://orcid.org/0000-0002-7837-3742)
- Yasunaru Sakuma (ORCID: https://orcid.org/0000-0003-3633-3221)
- Hideyuki Ohzawa (ORCID: https://orcid.org/0000-0001-9422-2840)
- Naohiro Sata (ORCID: https://orcid.org/0000-0002-6689-5623)
- Hideki Sasanuma (ORCID: https://orcid.org/0000-0002-9758-7295)
- Masanobu Taguchi (ORCID: https://orcid.org/0000-0003-3305-0314)
- Hironori Yamaguchi (ORCID: https://orcid.org/0000-0002-8371-9410)
- Masayuki Shinoda
- Kazuhiro Endo (ORCID: https://orcid.org/0000-0002-2845-3533)
- Joji Kitayama (ORCID: https://orcid.org/0000-0002-4075-1795)
- Naoki Sano (ORCID: https://orcid.org/0009-0007-9058-4431)
Institutions
- Jichi Medical University (JP)
Publication Details
- Journal
- Surgical Case Reports
- Published
- 2025-01-01
- DOI
- https://doi.org/10.70352/scrj.cr.25-0156
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Jichi Medical University